Rodman & Renshaw Reiterates Myrexis Market Outperform, $6 PT
Rodman & Renshaw reiterated its Myrexis (NASDAQ: MYRX) Market Outperform rating and $6 price target in a research report published today.
In the report, Rodman & Renshaw states, " Myrexis is trading well below its cash value despite an Hsp90 inhibitor in Phase 1 and two novel pre-clinical assets in the way of a cancer metabolism inhibitor and an oral anti-interferon program, both with differentiated mechanisms of action ripe for pharma partnering."
Later in the report, Rodman & Renshaw notes, "We believe the risk/reward profile of Myrexis shares is exceptionally favorable and recommend that investors build a position in the name."
Shares of Myrexis were trading at $2.70 at the time of posting, down 4.63% from Thursday's market close.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.